Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs

Akira Mamehara, Takeshi Sugimoto, Daisuke Sugiyama, SAHOKO Morinobu, Goh Tsuji, Seiji Kawano, Akio Morinobu, Shunichi Kumagai

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) have been studied extensively as prognostic markers of rheumatoid arthritis (RA). However, despite the fact that matrix metalloproteinase-3 (MMP-3) is linked to RA activity, few studies have evaluated MMP-3 as prognostic marker. Objective: To evaluate the performance of MMP-3 as predictor of joint destruction in RA treated with non-biological disease modifying anti-rheumatic drugs. Methods: In a retrospective study of 58 early to moderate stage RA patients who consulted the Department of Clinical Pathology and Immunology, Kobe University Hospital between May 2002 and April 2009, we evaluated the performance of MMP-3 and other biomarkers as predictors of joint destruction, by comparing them between radiographically progressive and non-progressive group. Results: Serum levels of RF at entry and ACPA, but not MMP-3 at entry, were significantly higher for the progressive group. Ratios of patients with MMP-3 levels higher than healthy control were not significantly different for the two groups. However, cutoff values determined through receiver operating characteristic analysis showed that the ratio of patients with elevated RF was significantly higher in the progressive group (p=0.001), while MMP-3 (p=0.092), ACPA (p=0.052), CRP (p=0.056), and ESR (p=0.069) tended to be more elevated in the progressive group. Multiple logistic regression analysis using the cutoff value identified MMP-3 positive and RF positive, but not ACPA, CRP or ESR, as significant factors for radiographic progression (OR 16.79 [95% CI: 1.34-414.19]). Conclusion: MMP-3 can be a useful marker for prediction of joint destruction.

Original languageEnglish
JournalKobe Journal of Medical Sciences
Volume56
Issue number3
Publication statusPublished - 2010
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 3
Antirheumatic Agents
Rheumatoid Arthritis
Joints
Rheumatoid Factor
Serum
Blood Sedimentation
C-Reactive Protein
Antibodies
Peptides
Clinical Pathology
Allergy and Immunology
ROC Curve
Retrospective Studies
Biomarkers
Logistic Models
Regression Analysis

Keywords

  • Disease modifying anti-rheumatic drugs
  • Matrix metalloproteinase-3
  • Radiographic progression
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. / Mamehara, Akira; Sugimoto, Takeshi; Sugiyama, Daisuke; Morinobu, SAHOKO; Tsuji, Goh; Kawano, Seiji; Morinobu, Akio; Kumagai, Shunichi.

In: Kobe Journal of Medical Sciences, Vol. 56, No. 3, 2010.

Research output: Contribution to journalArticle

Mamehara, Akira ; Sugimoto, Takeshi ; Sugiyama, Daisuke ; Morinobu, SAHOKO ; Tsuji, Goh ; Kawano, Seiji ; Morinobu, Akio ; Kumagai, Shunichi. / Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. In: Kobe Journal of Medical Sciences. 2010 ; Vol. 56, No. 3.
@article{1e22ba2bfbb14e43ae7ad581d4a7a339,
title = "Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs",
abstract = "Background: Rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) have been studied extensively as prognostic markers of rheumatoid arthritis (RA). However, despite the fact that matrix metalloproteinase-3 (MMP-3) is linked to RA activity, few studies have evaluated MMP-3 as prognostic marker. Objective: To evaluate the performance of MMP-3 as predictor of joint destruction in RA treated with non-biological disease modifying anti-rheumatic drugs. Methods: In a retrospective study of 58 early to moderate stage RA patients who consulted the Department of Clinical Pathology and Immunology, Kobe University Hospital between May 2002 and April 2009, we evaluated the performance of MMP-3 and other biomarkers as predictors of joint destruction, by comparing them between radiographically progressive and non-progressive group. Results: Serum levels of RF at entry and ACPA, but not MMP-3 at entry, were significantly higher for the progressive group. Ratios of patients with MMP-3 levels higher than healthy control were not significantly different for the two groups. However, cutoff values determined through receiver operating characteristic analysis showed that the ratio of patients with elevated RF was significantly higher in the progressive group (p=0.001), while MMP-3 (p=0.092), ACPA (p=0.052), CRP (p=0.056), and ESR (p=0.069) tended to be more elevated in the progressive group. Multiple logistic regression analysis using the cutoff value identified MMP-3 positive and RF positive, but not ACPA, CRP or ESR, as significant factors for radiographic progression (OR 16.79 [95{\%} CI: 1.34-414.19]). Conclusion: MMP-3 can be a useful marker for prediction of joint destruction.",
keywords = "Disease modifying anti-rheumatic drugs, Matrix metalloproteinase-3, Radiographic progression, Rheumatoid arthritis",
author = "Akira Mamehara and Takeshi Sugimoto and Daisuke Sugiyama and SAHOKO Morinobu and Goh Tsuji and Seiji Kawano and Akio Morinobu and Shunichi Kumagai",
year = "2010",
language = "English",
volume = "56",
journal = "Kobe Journal of Medical Sciences",
issn = "0023-2513",
publisher = "Kobe University School of Medicine",
number = "3",

}

TY - JOUR

T1 - Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs

AU - Mamehara, Akira

AU - Sugimoto, Takeshi

AU - Sugiyama, Daisuke

AU - Morinobu, SAHOKO

AU - Tsuji, Goh

AU - Kawano, Seiji

AU - Morinobu, Akio

AU - Kumagai, Shunichi

PY - 2010

Y1 - 2010

N2 - Background: Rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) have been studied extensively as prognostic markers of rheumatoid arthritis (RA). However, despite the fact that matrix metalloproteinase-3 (MMP-3) is linked to RA activity, few studies have evaluated MMP-3 as prognostic marker. Objective: To evaluate the performance of MMP-3 as predictor of joint destruction in RA treated with non-biological disease modifying anti-rheumatic drugs. Methods: In a retrospective study of 58 early to moderate stage RA patients who consulted the Department of Clinical Pathology and Immunology, Kobe University Hospital between May 2002 and April 2009, we evaluated the performance of MMP-3 and other biomarkers as predictors of joint destruction, by comparing them between radiographically progressive and non-progressive group. Results: Serum levels of RF at entry and ACPA, but not MMP-3 at entry, were significantly higher for the progressive group. Ratios of patients with MMP-3 levels higher than healthy control were not significantly different for the two groups. However, cutoff values determined through receiver operating characteristic analysis showed that the ratio of patients with elevated RF was significantly higher in the progressive group (p=0.001), while MMP-3 (p=0.092), ACPA (p=0.052), CRP (p=0.056), and ESR (p=0.069) tended to be more elevated in the progressive group. Multiple logistic regression analysis using the cutoff value identified MMP-3 positive and RF positive, but not ACPA, CRP or ESR, as significant factors for radiographic progression (OR 16.79 [95% CI: 1.34-414.19]). Conclusion: MMP-3 can be a useful marker for prediction of joint destruction.

AB - Background: Rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) have been studied extensively as prognostic markers of rheumatoid arthritis (RA). However, despite the fact that matrix metalloproteinase-3 (MMP-3) is linked to RA activity, few studies have evaluated MMP-3 as prognostic marker. Objective: To evaluate the performance of MMP-3 as predictor of joint destruction in RA treated with non-biological disease modifying anti-rheumatic drugs. Methods: In a retrospective study of 58 early to moderate stage RA patients who consulted the Department of Clinical Pathology and Immunology, Kobe University Hospital between May 2002 and April 2009, we evaluated the performance of MMP-3 and other biomarkers as predictors of joint destruction, by comparing them between radiographically progressive and non-progressive group. Results: Serum levels of RF at entry and ACPA, but not MMP-3 at entry, were significantly higher for the progressive group. Ratios of patients with MMP-3 levels higher than healthy control were not significantly different for the two groups. However, cutoff values determined through receiver operating characteristic analysis showed that the ratio of patients with elevated RF was significantly higher in the progressive group (p=0.001), while MMP-3 (p=0.092), ACPA (p=0.052), CRP (p=0.056), and ESR (p=0.069) tended to be more elevated in the progressive group. Multiple logistic regression analysis using the cutoff value identified MMP-3 positive and RF positive, but not ACPA, CRP or ESR, as significant factors for radiographic progression (OR 16.79 [95% CI: 1.34-414.19]). Conclusion: MMP-3 can be a useful marker for prediction of joint destruction.

KW - Disease modifying anti-rheumatic drugs

KW - Matrix metalloproteinase-3

KW - Radiographic progression

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=77958568501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958568501&partnerID=8YFLogxK

M3 - Article

VL - 56

JO - Kobe Journal of Medical Sciences

JF - Kobe Journal of Medical Sciences

SN - 0023-2513

IS - 3

ER -